Table 2.
Enriched pathways, gene ontologies, and diseases associated with C3/C5/C3AR1/C5AR1 SNV co-occurring genes.
| H. | ID | Name | p-Value | FDR B&H | FDR B&Y | Bonferroni |
|---|---|---|---|---|---|---|
| GO:Molecular Function | GO:0004875 | complement receptor activity | 8.290 × 10−8 | 1.981 × 10−5 | 1.200 × 10−4 | 1.981 × 10−5 |
| GO:0004878 | complement component C5a receptor activity | 4.219 × 10−6 | 3.361 × 10−4 | 2.036 × 10−3 | 1.008 × 10−3 | |
| GO:0001856 | complement component C5a binding | 4.219 × 10−6 | 3.361 × 10−4 | 2.036 × 10−3 | 1.008 × 10−3 | |
| GO:0001848 | complement binding | 2.091 × 10−5 | 1.249 × 10−3 | 7.566 × 10−3 | 4.998 × 10−3 | |
| GO:0001847 | opsonin receptor activity | 4.194 × 10−5 | 2.005 × 10−3 | 1.214 × 10−2 | 1.002 × 10−2 | |
| ID | Name | p-Value | FDR B&H | FDR B&Y | Bonferroni | |
| GO: Biological Process | GO:0010575 | positive regulation of vascular endothelial growth factor production | 3.378 × 10−7 | 5.327 × 10−4 | 4.230 × 10−3 | 5.327 × 10−4 |
| GO:0002430 | complement receptor-mediated signaling pathway | 2.205 × 10−6 | 8.695 × 10−4 | 6.905 × 10−3 | 3.478 × 10−3 | |
| GO:0030449 | regulation of complement activation | 3.684 × 10−6 | 1.064 × 10−3 | 8.449 × 10−3 | 5.809 × 10−3 | |
| GO:0038178 | complement component C5a signaling pathway | 4.048 × 10−6 | 1.064 × 10−3 | 8.449 × 10−3 | 6.384 × 10−3 | |
| GO:0002688 | regulation of leukocyte chemotaxis | 4.911 × 10−6 | 1.106 × 10−3 | 8.786 × 10−3 | 7.745 × 10−3 | |
| GO:0002920 | regulation of humoral immune response | 8.615 × 10−6 | 1.601 × 10−3 | 1.271 × 10−2 | 1.359 × 10−2 | |
| GO:0010758 | regulation of macrophage chemotaxis | 3.723 × 10−5 | 5.338 × 10−3 | 4.239 × 10−2 | 5.872 × 10−2 | |
| GO:0090022 | regulation of neutrophil chemotaxis | 4.479 × 10−5 | 5.887 × 10−3 | 4.675 × 10−2 | 7.064 × 10−2 | |
| GO:0030593 | neutrophil chemotaxis | 8.376 × 10−5 | 7.812 × 10−3 | 6.204 × 10−2 | 1.321 × 10−1 | |
| GO:0002685 | regulation of leukocyte migration | 8.422 × 10−5 | 7.812 × 10−3 | 6.204 × 10−2 | 1.328 × 10−1 | |
| GO:0097529 | myeloid leukocyte migration | 1.101 × 10−4 | 8.171 × 10−3 | 6.488 × 10−2 | 1.736 × 10−1 | |
| GO:1905521 | regulation of macrophage migration | 1.117 × 10−4 | 8.171 × 10−3 | 6.488 × 10−2 | 1.762 × 10−1 | |
| GO:0002253 | activation of immune response | 1.162 × 10−4 | 8.171 × 10−3 | 6.488 × 10−2 | 1.832 × 10−1 | |
| ID | Name | p-Value | FDR B&H | FDR B&Y | Bonferroni | |
| Pathway | 1269250 | Regulation of Complement cascade | 3.005 × 10−9 | 1.337 × 10−6 | 8.929 × 10−6 | 1.337 × 10−6 |
| 1269241 | Complement cascade | 1.130 × 10−7 | 2.513 × 10−5 | 1.678 × 10−4 | 5.027 × 10−5 | |
| 172846 | Staphylococcus aureus infection | 6.804 × 10−6 | 1.009 × 10−3 | 6.739 × 10−3 | 3.028 × 10−3 | |
| M16894 | Complement and coagulation cascades | 1.570 × 10−5 | 1.747 × 10−3 | 1.166 × 10−2 | 6.986 × 10−3 | |
| 83073 | Complement and coagulation cascades | 2.687 × 10−5 | 2.391 × 10−3 | 1.597 × 10−2 | 1.196 × 10−2 | |
| 1269546 | Peptide ligand-binding receptors | 5.391 × 10−5 | 3.999 × 10−3 | 2.670 × 10−2 | 2.399 × 10−2 | |
| 1269203 | Innate Immune System | 6.409 × 10−5 | 4.075 × 10−3 | 2.720 × 10−2 | 2.852 × 10−2 | |
| 1269248 | Activation of C3 and C5 | 1.007 × 10−4 | 5.603 × 10−3 | 3.741 × 10−2 | 4.483 × 10−2 | |
| M22072 | Alternative Complement Pathway | 1.722 × 10−4 | 8.515 × 10−3 | 5.685 × 10−2 | 7.663 × 10−2 | |
| ID | Name | p-Value | FDR B&H | FDR B&Y | Bonferroni | |
| Diseases | C0025306 | Meningococcemia | 4.257 × 10−8 | 5.364 × 10−5 | 4.139 × 10−4 | 5.364 × 10−5 |
| C2931788 | Atypical Hemolytic Uremic Syndrome | 2.466 × 10−6 | 1.554 × 10−3 | 1.199 × 10−2 | 3.107 × 10−3 | |
| C0020951 | Immune Complex Diseases | 6.637 × 10−5 | 1.394 × 10−2 | 1.076 × 10−1 | 8.363 × 10−2 | |
| C0003907 | Arthus Reaction | 1.417 × 10−4 | 1.984 × 10−2 | 1.531 × 10−1 | 1.786 × 10−1 | |
| C2717961 | Thrombotic Microangiopathies | 1.729 × 10−4 | 2.001 × 10−2 | 1.544 × 10−1 | 2.178 × 10−1 | |
| C0740345 | Germ Cell Cancer | 3.289 × 10−4 | 2.072 × 10−2 | 1.599 × 10−1 | 4.144 × 10−1 | |
| C0027654 | Embryonal Neoplasm | 3.289 × 10−4 | 2.072 × 10−2 | 1.599 × 10−1 | 4.144 × 10−1 | |
| C0027658 | Neoplasms, Germ Cell, and Embryonal | 3.289 × 10−4 | 2.072 × 10−2 | 1.599 × 10−1 | 4.144 × 10−1 | |
| C0751364 | Cancer, Embryonal | 3.289 × 10−4 | 2.072 × 10−2 | 1.599 × 10−1 | 4.144 × 10−1 | |
| C0003257 | Antibody Deficiency Syndrome | 4.250 × 10−4 | 2.550 × 10−2 | 1.968 × 10−1 | 5.355 × 10−1 | |
| C0008149 | Chlamydia Infections | 5.355 × 10−4 | 2.550 × 10−2 | 1.968 × 10−1 | 6.747 × 10−1 | |
| C0021051 | Immunologic Deficiency Syndromes | 7.852 × 10−4 | 2.550 × 10−2 | 1.968 × 10−1 | 9.894 × 10−1 | |
| C1319860 | Sendai virus infection | 9.290 × 10−4 | 2.550 × 10−2 | 1.968 × 10−1 | 1.000 | |
| C0221238 | Mesangial proliferative glomerulonephritis | 1.252 × 10−3 | 2.550 × 10−2 | 1.968 × 10−1 | 1.000 | |
| C0272242 | Complement deficiency disease | 1.620 × 10−3 | 2.550 × 10−2 | 1.968 × 10−1 | 1.000 |